Huitema ADR - Search Results

1

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.

van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, Steeghs N. van der Kleij MBA, et al. Among authors: huitema adr. Clin Pharmacokinet. 2023 Oct;62(10):1333-1364. doi: 10.1007/s40262-023-01293-9. Epub 2023 Aug 16. Clin Pharmacokinet. 2023. PMID: 37584840 Free PMC article. Review.

2

Drug interactions between antiretroviral drugs and comedicated agents.

de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. de Maat MM, et al. Clin Pharmacokinet. 2003;42(3):223-82. doi: 10.2165/00003088-200342030-00002. Clin Pharmacokinet. 2003. PMID: 12603174 Review.

3

Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH. Kappelhoff BS, et al. Clin Pharmacokinet. 2004;43(13):845-53. doi: 10.2165/00003088-200443130-00002. Clin Pharmacokinet. 2004. PMID: 15509183 Review.

4

Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.

de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. de Jonge ME, et al. Clin Pharmacokinet. 2005;44(2):147-73. doi: 10.2165/00003088-200544020-00002. Clin Pharmacokinet. 2005. PMID: 15656695 Review.

5

Clinical pharmacokinetics of cyclophosphamide.

de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. de Jonge ME, et al. Clin Pharmacokinet. 2005;44(11):1135-64. doi: 10.2165/00003088-200544110-00003. Clin Pharmacokinet. 2005. PMID: 16231966 Review.

6

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD. Zandvliet AS, et al. Clin Pharmacokinet. 2008;47(8):487-513. doi: 10.2165/00003088-200847080-00001. Clin Pharmacokinet. 2008. PMID: 18611060 Review.

7

Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.

Koolen SL, Huitema AD, Jansen RS, van Voorthuizen T, Beijnen JH, Smit WM, Schellens JH. Koolen SL, et al. Oncologist. 2009 Sep;14(9):944-8. doi: 10.1634/theoncologist.2009-0111. Epub 2009 Sep 2. Oncologist. 2009. PMID: 19726456 Free article. Review.

8

Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.

Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Koolen SL, et al. Br J Clin Pharmacol. 2010 May;69(5):465-74. doi: 10.1111/j.1365-2125.2010.03621.x. Br J Clin Pharmacol. 2010. PMID: 20573082 Free PMC article. Clinical Trial.

9

Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Keizer RJ, et al. Clin Pharmacokinet. 2010 Aug;49(8):493-507. doi: 10.2165/11531280-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20608753 Review.

10

From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies.

Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD. Koolen SL, et al. J Clin Pharmacol. 2012 Mar;52(3):370-80. doi: 10.1177/0091270010397051. Epub 2011 Apr 19. J Clin Pharmacol. 2012. PMID: 21505085

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

489 results

Search Page